Randy Jensen
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
Background Social determinants of health (SDOHs) may impact outcomes of patients with high-grade glioma (HGG). We examined the effect of rurality and socioeconomic status on treatment and survival of patients with newly diagnosed HGG. Methods This retrospective analysis used 2 cohorts from the Utah Cancer Registry, including all patients diagnosed with HGG (2000-2019) (cohort 1) and all HGG patients who underwent surgery (2000-2020) (cohort 2). Patient demographics were evaluated descriptively. Kaplan-Meier curves, log-rank tests, and multivariable Cox regression analysis were used for survival analyses. Results Patients from cohort 1 living in Frontier (n = 60), Rural (n = 363), and Urban (n = 1502) Utah traveled mean distances of 95.9 ± 69.7, 50.0 ± 66.5, and 10.7 ± 11.3 miles, respectively, for treatment (P < .001). Urban patients were diagnosed at a younger age (54.2 ± 20.2 years) than patients from Frontier (56.8 ± 20.3 years) and Rural (57.3 ± 17.6 years) areas (P < .019). Frontier patients were more likely to have lower income than Urban patients (30.7% vs 65.5%, P < .001). Rural patients (13.0 months [95% CI 11.2-14.8]) experienced shorter median survival than Urban patients (16 months [95% CI 14.3-17.7]) (P = .049). Among patients undergoing surgery, those with private insurance (54.2%, P < .001) and in high-income (60.2%, P = .007) and socioeconomic (60.4%, P = .005) quartiles received adjuvant chemotherapy and radiation more frequently. Conclusion HGG patients from Frontier and Rural counties in Utah encountered greater SDOH barriers without experiencing delays in resection. Rural patients had shorter survival than Urban patients. Further investigation is needed to determine whether additional SDOHs (income and insurance status) may intersect and contribute to shorter survival and less access to adjuvant therapy.
Year:
2025
Background Glioblastoma (GBM) has a median survival of <2 years. Pexidartinib (PLX3397) is a small-molecule inhibitor of CSF1R, KIT, and oncogenic FTL3, which are implicated in GBM treatment resistance. Results from glioma models indicate that combining radiation therapy (RT) and pexidartinib reduces radiation resistance. We added pexidartinib to standard-of-care RT/temozolomide (TMZ) in patients with newly diagnosed GBM to assess the therapeutic benefit of altering the tumor microenvironment with pexidartinib. Methods In this open-label, dose-escalation, multicenter, Phase 1b/2 trial, pexidartinib was administered in combination with RT/TMZ followed by adjuvant pexidartinib + TMZ. During Phase 1b, pexidartinib was given 5 or 7 days/week at multiple dosing levels. The primary Phase 1b endpoint was the recommended Phase 2 dose (RP2D). Phase 2 patients received the RP2D with the primary endpoint of median progression-free survival (mPFS). Secondary objectives were median overall survival (mOS), pharmacokinetics, and safety. Results The RP2D of pexidartinib was 800 mg/day for 5 days/week during RT/TMZ, followed by 800 mg/day for 7 days/week with adjuvant TMZ. mPFS was 6.7 months (90% CI: 4.5, 11.5) for the modified intention-to-treat population. The actual mOS was 13.1 months (90% CI: 11.5, 24.5), and the mOS corrected for comparison with matched historical controls was 18.8 months (95% CI: 12.6, 28.0). Conclusions This trial established the RP2D of pexidartinib in combination with RT/TMZ and adjuvant TMZ. Pexidartinib was generally safe and well tolerated. Although the study regimen with pexidartinib was not efficacious, pharmacodynamic studies showed modulation of systemic markers that could lead to alteration of the tumor microenvironment.
Year:
2024
Supplemental Figure S13. Relative to the overall median read depth for each sample, the median read depth for the TERT promoter is less compared to other gene-specific regions (IDH1, IDH2, and NF1).
Year:
2024
Supplemental Figure S17. A heatmap of all discovered somatic mutations demonstrates the diversity of genes involved and the clustering of mutations in specific genes associated with different adult diffuse gliomas.
Year:
2024
Supplemental Figure S17. A heatmap of all discovered somatic mutations demonstrates the diversity of genes involved and the clustering of mutations in specific genes associated with different adult diffuse gliomas.
Year:
2024
Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous brain tissue of the peritumoral edema. Here, we developed and validated True2 sequencing to reduce NGS-associated errors to Significance: True2 is a next-generation sequencing workflow that facilitates unbiased discovery of somatic mutations across the full range of variant allele frequencies, which could help identify residual disease vulnerabilities for targeted adjuvant therapies.
Year:
2024
Supplemental Figure S13. Relative to the overall median read depth for each sample, the median read depth for the TERT promoter is less compared to other gene-specific regions (IDH1, IDH2, and NF1).
Year:
2024
Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous brain tissue of the peritumoral edema. Here, we developed and validated True2 sequencing to reduce NGS-associated errors to Significance: True2 is a next-generation sequencing workflow that facilitates unbiased discovery of somatic mutations across the full range of variant allele frequencies, which could help identify residual disease vulnerabilities for targeted adjuvant therapies.
Year:
2024
Collaborators (5)
Adam L Cohen
University of Utah
Tobias Walbert
-
Drew Sellers
Research Associate Professor
University of Washington
Michael Karsy
University of Michigan
Howard Colman
Professor
-
Make your next move.
Prepare your application
Review drafts before you send them.